Filing Details
- Accession Number:
- 0000904454-20-000586
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-20 18:14:47
- Reporting Period:
- 2020-08-18
- Accepted Time:
- 2020-08-20 18:14:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1000694 | Novavax Inc | NVAX | Biological Products, (No Disgnostic Substances) (2836) | 222816046 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1342823 | M Gregory Glenn | C/O Novavax, Inc. 21 Firstfield Road Gaithersburg MD 20878 | President, R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-08-18 | 3,200 | $50.00 | 5,039 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-08-18 | 7,500 | $25.60 | 12,539 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-08-18 | 4,405 | $36.60 | 16,944 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-08-18 | 8,200 | $27.00 | 25,144 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-08-18 | 2,733 | $27.00 | 27,877 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-08-18 | 16,658 | $27.60 | 44,535 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-08-18 | 13,225 | $46.00 | 57,760 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-08-18 | 6,288 | $143.94 | 51,472 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-08-18 | 31,957 | $145.00 | 19,515 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-08-18 | 17,151 | $146.00 | 2,364 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-08-18 | 525 | $146.58 | 1,839 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-08-18 | 1,528 | $0.00 | 311 | No | 5 | G | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 5 | G | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-18 | 3,200 | $0.00 | 3,200 | $50.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-18 | 7,500 | $0.00 | 7,500 | $25.60 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-18 | 4,405 | $0.00 | 4,405 | $36.60 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-18 | 8,200 | $0.00 | 8,200 | $27.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-18 | 2,733 | $0.00 | 2,733 | $27.00 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-18 | 16,658 | $0.00 | 16,658 | $27.60 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-08-18 | 13,225 | $0.00 | 13,225 | $46.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2021-03-10 | No | 4 | M | Direct | |
| 0 | 2022-03-01 | No | 4 | M | Direct | |
| 0 | 2023-03-02 | No | 4 | M | Direct | |
| 550 | 2026-11-14 | No | 4 | M | Direct | |
| 6,017 | 2026-11-14 | No | 4 | M | Direct | |
| 8,341 | 2027-12-15 | No | 4 | M | Direct | |
| 18,524 | 2028-12-13 | No | 4 | M | Direct |
Footnotes
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.45 to $144.43, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.45 to $145.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.47 to $146.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
- The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.47 to $146.67, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.
- The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 10, 2011 grant date.
- The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 1, 2012 grant date.
- The shares subject to this option grant vested in four equal annual installments beginning on the first anniversary of the March 2, 2013 grant date.
- Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
- Vesting of the shares subject to this option grant is subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments on the first of each month over the following three (3) years, subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested or will vest if, at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of the Company's common stock meets or exceeds $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days.
- Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, subject to continued employment through such vesting date.
- Twenty-five percent (25%) of the shares subject to this option grant vested on the first anniversary of the December 13, 2018 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through such vesting date.
Billionaire Hedge Funds
